PDCD1 and non-small cell lung carcinoma: Some bispecific antibodies, capable of simultaneously binding PD-1/PD-L1 and CTLA-4 with high affinity, are also being evaluated in ongoing clinical trials (Table 2).465,466 KN046, a novel bispecific antibody that blocks PD-L1 interaction with PD-1 and CTLA-4 interaction with CD80/CD86, was well tolerated and effective in treating advanced NSCLC, with promising PFS and OS benefits in LSCC.465 Pivotal Phase III clinical trials in advanced unresectable or metastatic LSCC is currently ongoing for this bispecific antibody (NCT04474119).